Biotech & Health Tech
Spyre’s arthritis misses; Ideaya ends eye cancer trial
Plus news about United Therapeutics. Spyre Therapeutics reports additional trial failures: The biotech said its long-acting anti-TL1A drug, codenamed SPY072, did not meet the primary endpoints in the psoriatic arthritis or ...
Plus news about United Therapeutics. Spyre Therapeutics reports additional trial failures: The biotech said its long-acting anti-TL1A drug, codenamed SPY072, did not meet the primary endpoints in the psoriatic arthritis or ...
This is a summary of the story. Read the full article at Endpoints News (Biopharma) ↗